EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA

Kerigo Ndirangu iD, Isabelle Chabot iD, Katie Lewis iD, Annabel Lambert iD, Qi Zhao, Melanie Lucero iD, Genevieve Meier iD

Future Oncology · 2024

DOI: 10.2217/fon-2022-1228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Kerigo Ndirangu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eisai Inc. Nutley, NJ 07110, USA. Hauptthemen laut MEDLINE: Quality of Life, Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To report treatment patterns and quality of life (QoL) in HER2-negative advanced breast cancer patients.

Methods

Data were drawn from a cross-sectional survey in Europe and USA.

Results

Hormone plus targeted therapy was the most frequent first-line (1L, 62%) and second-line (2L, 45%) treatment for HR+/HER2-patients. Chemotherapy was most frequent at third-line or greater (3L+, 39%) for HR+/HER2- patients, 2L (51%) and 3L+ (48%) for triple negative breast cancer (TNBC) patients. Time to progression was 13.8 (2L) and 11.0 (3L+) months for HR+/HER2- patients. No comparisons were observed for TNBC patients. EQ-5D-5L scores were highest in patients at 1L and lowest at 3L+.

Conclusion

Reduced QoL and treatment response were reported in patients at later lines of therapy. Breast cancer is the most common cancer in women. Differences in survival are seen depending on how widespread or advanced the cancer is, how many different treatments the patient has been given, as well as whether certain receptors on the tumor are present or absent. Many new treatments are available which can target these receptors. These treatments have improved survival in patients with advanced breast cancer, but other benefits for the patient are not always clear. In addition, differences between countries are possible as official guidance can vary. This study aimed to understand these issues, by asking physicians and their patients across Europe and USA for their views on quality of life and satisfaction with their treatments. We found that, in general, physicians prescribed treatments as recommended in the treatment guidelines. As breast cancer progressed and treatment stopped working, patients were switched on to different treatments. Survival, quality of life and treatment satisfaction were all worse in patients who had switched treatments. It appears that the patients lose confidence that their new treatment will work to improve their quality of life. We also saw differences in some of these outcomes between Europe and USA, which were likely due to differences in the treatment guidelines between countries. Both quality of life and treatment satisfaction are important for the well-being of patients with advanced breast cancer as they now live longer with these new treatments. This should be considered by physicians and taken into account for future work.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeErb-b2 Receptor Tyrosine KinasesBreast NeoplasmsHumansFemaleMiddle AgedUnited StatesCross-Sectional StudiesAgedAdultEuropeAntineoplastic Combined Chemotherapy ProtocolsTriple Negative Breast NeoplasmsNeoplasm StagingTreatment Outcome

Stichwörter der Autor:innen

advanced breast cancerhealthcare-related quality of lifemedical chart reviewmetastatic breast cancerreal-worldretrospectivetreatment linetreatment satisfaction

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Eisai Inc. Nutley, NJ 07110, USA.
  • Faculty of Pharmacy, University of Montreal, Quebec, H3T 1J4, Canada.
  • Adelphi Real World, Bollington, SK10 5JB, UK.
  • Formerly of Eisai Inc. Nutley, NJ 07110, USA.

ORCID-Profile: Kerigo Ndirangu, Isabelle Chabot, Katie Lewis, Annabel Lambert, Melanie Lucero, Genevieve Meier

Förderung

  • Eisai Inc.

Zitieren

APA

Ndirangu, K., Chabot, I., Lewis, K., Lambert, A., Zhao, Q., Lucero, M., & Meier, G. (2024). Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA. Future Oncology. https://doi.org/10.2217/fon-2022-1228

Vancouver

Ndirangu K, Chabot I, Lewis K, Lambert A, Zhao Q, Lucero M, et al. Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA. Future Oncology. 2024. doi:10.2217/fon-2022-1228

BibTeX
@article{Ndirangu2024,
  author = {Ndirangu, Kerigo and Chabot, Isabelle and Lewis, Katie and Lambert, Annabel and Zhao, Qi and Lucero, Melanie and Meier, Genevieve},
  title = {Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2022-1228}
}
Kostenlos starten →